PhRMA And AAM Urge New Approaches In Dealing With COVID-19 Supply Chain Disruptions

As costs and delays mount, the brand and generic groups seek government solutions. AAM continues to press for federal contracts, and PhRMA wants the Department of Transportation to use its enforcement discretion under CARES Act to mandate international flights. AAM survey finds pandemic has caused 224% spike in the cost of transporting drugs.

PS2005_Plane-Cargo_388724002_1200.jpg
Shutterstock • Source: Industry Groups Want Relief For COVID-19 Supply Chain Disruptions

Two major US pharmaceutical industry groups, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Association for Accessible Medicines (AAM), are appealing for new approaches in dealing with the problems that the COVID-19 pandemic has caused in the US pharmaceutical supply chain.

The AAM has reiterated its calls to move manufacturing back to the US, while PhRMA wants the US Department of...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Manufacturing

More from Compliance